TY - JOUR
KW - Adult
KW - Buprenorphine, Naloxone Drug Combination/therapeutic use
KW - Cognitive Dysfunction/complications/drug therapy
KW - Depression/drug therapy
KW - Female
KW - Humans
KW - Male
KW - Medication Adherence/psychology
KW - Middle Aged
KW - Narcotic Antagonists/therapeutic use
KW - Neuropsychological Tests
KW - Opiate Substitution Treatment/psychology
KW - Opioid-Related Disorders/complications/drug therapy
KW - Pilot Projects
KW - Adherence
KW - buprenorphine/naloxone
KW - Depression
KW - Neuropsychological change
KW - opioid agonist treatment
KW - opioid use disorder
AU - Travis M. Scott
AU - Monica Rivera Mindt
AU - Chinazo O. Cunningham
AU - Franchesca Arias
AU - Kelly Coulehan
AU - Aprille Mangalonzo
AU - Pat Olsen
AU - Julia H. Arnsten
A1 - 
AB - BACKGROUND: Among persons with opioid use disorder (OUD), neuropsychological dysfunction is associated with depression, and better neuropsychological function is associated with opioid abstinence. However, it is unknown whether depressive symptomatology or adherence to opiate agonist treatment are associated with neuropsychological change over time. METHODS: We recruited 20 buprenorphine/naloxone-treated adults with OUD (M Age = 45.2 years [SD = 8.1]; 25% female) to complete baseline and 6 month visits containing a neuropsychological test battery and self-reported measures of depressive symptomatology and medication adherence. RESULTS: Depressive symptomatology was not significantly related to neuropsychological change (p's > .05). Greater adherence to buprenorphine/naloxone was associated with improvements in learning, memory, and global functioning (r's = .52-60; p's < .05). CONCLUSIONS: Among OUD patients, greater adherence to buprenorphine/naloxone is associated with improved neuropsychological functioning over time. In contrast, depressive symptomatology is not associated with neuropsychological functioning over time. Supporting adherence to buprenorphine/naloxone may improve and/or preserve learning and memory functioning in individuals treated for OUD. TRIAL REGISTRATION: NCT01108679 . Registered 21 April 2010.
AD - Department of Psychology, Fordham University, Bronx, NY, 10458, USA. tshivleyscott@fordham.edu.; Department of Psychology, Fordham University, Bronx, NY, 10458, USA.; Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, 10467, USA.; Department of Psychology, University of Florida, Gainesville, FL, 32611, USA.; Department of Psychology, Fordham University, Bronx, NY, 10458, USA.; Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, 10467, USA.; Department of Psychology, Fordham University, Bronx, NY, 10458, USA.; Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, 10467, USA.
BT - Substance abuse treatment, prevention, and policy
C5 - Healthcare Disparities; Opioids & Substance Use
CP - 1
CY - England
DO - 10.1186/s13011-017-0133-2
IS - 1
JF - Substance abuse treatment, prevention, and policy
LA - eng
M1 - Journal Article
N2 - BACKGROUND: Among persons with opioid use disorder (OUD), neuropsychological dysfunction is associated with depression, and better neuropsychological function is associated with opioid abstinence. However, it is unknown whether depressive symptomatology or adherence to opiate agonist treatment are associated with neuropsychological change over time. METHODS: We recruited 20 buprenorphine/naloxone-treated adults with OUD (M Age = 45.2 years [SD = 8.1]; 25% female) to complete baseline and 6 month visits containing a neuropsychological test battery and self-reported measures of depressive symptomatology and medication adherence. RESULTS: Depressive symptomatology was not significantly related to neuropsychological change (p's > .05). Greater adherence to buprenorphine/naloxone was associated with improvements in learning, memory, and global functioning (r's = .52-60; p's < .05). CONCLUSIONS: Among OUD patients, greater adherence to buprenorphine/naloxone is associated with improved neuropsychological functioning over time. In contrast, depressive symptomatology is not associated with neuropsychological functioning over time. Supporting adherence to buprenorphine/naloxone may improve and/or preserve learning and memory functioning in individuals treated for OUD. TRIAL REGISTRATION: NCT01108679 . Registered 21 April 2010.
PP - England
PY - 2017
SN - 1747-597X; 1747-597X
SP - 48
T1 - Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study
T2 - Substance abuse treatment, prevention, and policy
TI - Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study
U1 - Healthcare Disparities; Opioids & Substance Use
U2 - 29141650
U3 - 10.1186/s13011-017-0133-2
VL - 12
VO - 1747-597X; 1747-597X
Y1 - 2017
Y2 - Nov 15
ER -